.Attribute Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a typical consequence of 11 months, people with metastatic intestinal tumors that received biomarker-matched treatments based upon circulating lump DNA profiling showed a better scientific perk than those getting unparalleled treatment.